Akums Drugs and Pharmaceuticals Ltd has been assigned an ESG rating of 63 for the Financial Year 2024-25. This rating was issued by NSE Sustainability Ratings & Analytics Limited, a subsidiary of NSE Indices Limited. The company clarified that it did not formally engage the agency for this assessment; rather, the rating was assigned voluntarily based on publicly available information about the firm’s environmental, social, and governance practices.
Understanding the ESG Assessment
On May 7, 2026, Akums Drugs and Pharmaceuticals Ltd was notified of its latest sustainability performance assessment. The company received a score of 63 from NSE Sustainability Ratings & Analytics Limited for the 2024-25 fiscal period. This rating reflects the organization’s commitment to transparency and its efforts in maintaining sustainable business practices within the pharmaceutical sector.
Context of the Rating
It is important to note that this evaluation was conducted independently by the rating provider. Akums Drugs and Pharmaceuticals Ltd has confirmed that it did not initiate a professional engagement or pay for this specific service. The score was derived entirely through the analysis of publicly available information. Investors and stakeholders can review the detailed breakdown of this rating through the official portal provided by the assessing agency.
Source: BSE
